Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw

Y. H. Cha, N. Hong, Y. Rhee, I. H. Cha

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Although osteoradionecrosis (ORN) is a serious complication of craniofacial radiotherapy, the current management methods remain suboptimal. Teriparatide (TPTD), a recombinant human parathyroid hormone (1–34), has shown beneficial effects on osseous regeneration in medication-related osteonecrosis of the jaw or periodontitis. However, TPTD therapy in irradiated bones has not been indicated yet because of the theoretical risk of osteosarcoma seen in rat models. Hence, we first report here two patients with tongue cancer with late-emerging ORN who were successfully treated with TPTD for 4–6 months with serum calcium and vitamin D supplementation. In contrast to the usual progress of ORN, the bone defect regenerated well and bone turnover markers including serum C-terminal telopeptide of type 1 collagen and osteocalcin were restored with TPTD therapy. Our experience might suggest that TPTD therapy with careful monitoring can provide an effective treatment option for patients with ORN in select refractory cases, with the benefits outweighing the potential risks.

Original languageEnglish
Pages (from-to)987-992
Number of pages6
JournalOsteoporosis International
Issue number4
Publication statusPublished - 2018 Apr 1

Bibliographical note

Publisher Copyright:
© 2017, International Osteoporosis Foundation and National Osteoporosis Foundation.

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Teriparatide therapy for severe, refractory osteoradionecrosis of the jaw'. Together they form a unique fingerprint.

Cite this